These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 8759643)

  • 1. Aza-peptide analogs as potent human immunodeficiency virus type-1 protease inhibitors with oral bioavailability.
    Fässler A; Bold G; Capraro HG; Cozens R; Mestan J; Poncioni B; Rösel J; Tintelnot-Blomley M; Lang M
    J Med Chem; 1996 Aug; 39(16):3203-16. PubMed ID: 8759643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development.
    Bold G; Fässler A; Capraro HG; Cozens R; Klimkait T; Lazdins J; Mestan J; Poncioni B; Rösel J; Stover D; Tintelnot-Blomley M; Acemoglu F; Beck W; Boss E; Eschbach M; Hürlimann T; Masso E; Roussel S; Ucci-Stoll K; Wyss D; Lang M
    J Med Chem; 1998 Aug; 41(18):3387-401. PubMed ID: 9719591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent human immunodeficiency virus type 1 protease inhibitors that utilize noncoded D-amino acids as P2/P3 ligands.
    Jungheim LN; Shepherd TA; Baxter AJ; Burgess J; Hatch SD; Lubbehusen P; Wiskerchen M; Muesing MA
    J Med Chem; 1996 Jan; 39(1):96-108. PubMed ID: 8568831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paracyclophanes: a novel class of water-soluble inhibitors of HIV proteinase.
    Ettmayer P; Billich A; Hecht P; Rosenwirth B; Gstach H
    J Med Chem; 1996 Aug; 39(17):3291-9. PubMed ID: 8765512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere.
    Beaulieu PL; Wernic D; Abraham A; Anderson PC; Bogri T; Bousquet Y; Croteau G; Guse I; Lamarre D; Liard F; Paris W; Thibeault D; Pav S; Tong L
    J Med Chem; 1997 Jul; 40(14):2164-76. PubMed ID: 9216835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of human immunodeficiency virus type 1 protease containing 2-aminobenzyl-substituted 4-amino-3-hydroxy-5-phenylpentanoic acid: synthesis, activity, and oral bioavailability.
    Lehr P; Billich A; Charpiot B; Ettmayer P; Scholz D; Rosenwirth B; Gstach H
    J Med Chem; 1996 May; 39(10):2060-7. PubMed ID: 8642565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bis tertiary amide inhibitors of the HIV-1 protease generated via protein structure-based iterative design.
    Melnick M; Reich SH; Lewis KK; Mitchell LJ; Nguyen D; Trippe AJ; Dawson H; Davies JF; Appelt K; Wu BW; Musick L; Gehlhaar DK; Webber S; Shetty B; Kosa M; Kahil D; Andrada D
    J Med Chem; 1996 Jul; 39(14):2795-811. PubMed ID: 8709110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.
    Kaldor SW; Kalish VJ; Davies JF; Shetty BV; Fritz JE; Appelt K; Burgess JA; Campanale KM; Chirgadze NY; Clawson DK; Dressman BA; Hatch SD; Khalil DA; Kosa MB; Lubbehusen PP; Muesing MA; Patick AK; Reich SH; Su KS; Tatlock JH
    J Med Chem; 1997 Nov; 40(24):3979-85. PubMed ID: 9397180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small dipeptide-based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic.
    Kiso Y; Matsumoto H; Mizumoto S; Kimura T; Fujiwara Y; Akaji K
    Biopolymers; 1999; 51(1):59-68. PubMed ID: 10380353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 protease inhibitors: synthesis and biological evaluation of glycopeptidemimetics.
    Ghosh AK; McKee SP; Sanders WM; Darke PL; Zugay JA; Emini EA; Schleif WA; Quintero JC; Huff JR; Anderson PS
    Drug Des Discov; 1993; 10(1):77-88. PubMed ID: 8399995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.
    Mimoto T; Kato R; Takaku H; Nojima S; Terashima K; Misawa S; Fukazawa T; Ueno T; Sato H; Shintani M; Kiso Y; Hayashi H
    J Med Chem; 1999 May; 42(10):1789-802. PubMed ID: 10346931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors.
    Randolph JT; Huang PP; Flosi WJ; DeGoey D; Klein LL; Yeung CM; Flentge C; Sun M; Zhao C; Dekhtyar T; Mo H; Colletti L; Kati W; Marsh KC; Molla A; Kempf DJ
    Bioorg Med Chem; 2006 Jun; 14(12):4035-46. PubMed ID: 16504523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.
    Ghosh AK; Swanson LM; Cho H; Leshchenko S; Hussain KA; Kay S; Walters DE; Koh Y; Mitsuya H
    J Med Chem; 2005 May; 48(10):3576-85. PubMed ID: 15887965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket.
    Hidaka K; Kimura T; Abdel-Rahman HM; Nguyen JT; McDaniel KF; Kohlbrenner WE; Molla A; Adachi M; Tamada T; Kuroki R; Katsuki N; Tanaka Y; Matsumoto H; Wang J; Hayashi Y; Kempf DJ; Kiso Y
    J Med Chem; 2009 Dec; 52(23):7604-17. PubMed ID: 19954246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells.
    Mahalingam AK; Axelsson L; Ekegren JK; Wannberg J; Kihlström J; Unge T; Wallberg H; Samuelsson B; Larhed M; Hallberg A
    J Med Chem; 2010 Jan; 53(2):607-15. PubMed ID: 19961222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
    Ghosh AK; Kincaid JF; Walters DE; Chen Y; Chaudhuri NC; Thompson WJ; Culberson C; Fitzgerald PM; Lee HY; McKee SP; Munson PM; Duong TT; Darke PL; Zugay JA; Schleif WA; Axel MG; Lin J; Huff JR
    J Med Chem; 1996 Aug; 39(17):3278-90. PubMed ID: 8765511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
    Mimoto T; Nojima S; Terashima K; Takaku H; Shintani M; Hayashi H
    Bioorg Med Chem; 2008 Feb; 16(3):1299-308. PubMed ID: 17981045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereospecific synthesis, structure-activity relationship, and oral bioavailability of tetrahydropyrimidin-2-one HIV protease inhibitors.
    De Lucca GV; Liang J; De Lucca I
    J Med Chem; 1999 Jan; 42(1):135-52. PubMed ID: 9888839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV protease inhibitors: synthesis and activity of N-aryl-N'-hydroxyalkyl hydrazide pseudopeptides.
    Marastoni M; Baldisserotto A; Trapella C; McDonald J; Bortolotti F; Tomatis R
    Eur J Med Chem; 2005 May; 40(5):445-51. PubMed ID: 15893018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of non-natural D-amino acid derivatives and allophenylnorstatine-dimethylthioproline scaffold in HIV protease inhibitors have high efficacy in mutant HIV.
    Nakatani S; Hidaka K; Ami E; Nakahara K; Sato A; Nguyen JT; Hamada Y; Hori Y; Ohnishi N; Nagai A; Kimura T; Hayashi Y; Kiso Y
    J Med Chem; 2008 May; 51(10):2992-3004. PubMed ID: 18426195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.